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Abstract
The drug edelfosine is a synthetic analog of 2-lysophosphatidylcholine. Edelfosine is incorporated by highly proliferating
cells, e.g. activated immune cells. It acts on cellular membranes by selectively aggregating the cell death receptor Fas in
membrane rafts and interference with phosphatidylcholine (PC) synthesis with subsequent induction of apoptosis.
Edelfosine has been proposed for the treatment of autoimmune diseases like multiple sclerosis (MS). Earlier studies on the
animal model of MS, experimental autoimmune encephalomyelitis (EAE), have generated first evidence for the efficacy of
edelfosine treatment. However, it is unknown if the previously described mechanisms for edelfosine action, which are
derived from in vitro studies, are solely responsible for the amelioration of EAE or if edelfosine may exert additional effects,
which may be beneficial in the context of autoimmunity. Since it was the purpose of our studies to assess the potential
usefulness of edelfosine for the treatment of MS, we examined its mechanism/s of action on immune functions in human T
cells. Low doses of edelfosine led to a decrease in homeostatic proliferation, and further studies of the mechanism/s of
action by genome-wide transcriptional profiling showed that edelfosine reduces the expression of MHC class II molecules,
of molecules involved in MHC class II-associated processing and presentation, and finally upregulated a series of type I
interferon-associated genes. The inhibition of homeostatic proliferation, as well as the effects on MHC class II expression and
–presentation, and the induction of type I interferon-associated genes are novel and interesting in the context of
developing edelfosine for clinical use in MS and possibly also other T cell-mediated autoimmune diseases.
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Introduction
The 2-lysophosphatidylcholine analog edelfosine (1-O-octade-
cyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-18-OCH3) was
synthesized in 1969 [1]. In 1979 Andreesen et al. already reported
that 5 mg/ml edelfosine selectively induced cell death in mitogen-
activated human peripheral blood lymphocytes (PBLs) in vitro,
whereas the viability of resting PBLs was not impaired [2]. Later,
edelfosine was shown to selectively induce apoptosis in leukemic
cells [3]. In 1999, Cabaner et al. examined the mechanisms of
immunomodulation by edelfosine [4], and their findings implied
that apoptosis induction is not only the main principle leading to
the drug’s antitumor activity, but might also account for its
immunomodulatory effects. In contrast to other cytotoxic drugs,
alkyl lysophospholipids (ALPs) do not target the DNA. Edelfosine
induces apoptosis by recruitment of Fas/CD95 and subsequent
death-inducing signaling complex (DISC) formation in a lipid raft-
mediated process thereby exerting its cytotoxic activity in the
absence of FasL [5,6]. Additionally, edelfosine may accumulate in
lipid rafts within the plasma membrane followed by endocytosis
and translocation to the intracellular location of the CTP:pho-
sphocholine cytidylyltransferase (CCT), the endoplasmic reticulum
[7,8]. Here, edelfosine inhibits the de novo biosynthesis of PC and
lipid second messenger-based signal transduction pathways leading
to mitotic arrest and apoptosis [9]. Thus, ALPs like edelfosine may
affect several cellular processes, some probably specifically on
certain cell types but with the main outcome of apoptosis
induction. The degree of cellular edelfosine uptake and thus
apoptosis correlates with the proliferative activity and the
associated metabolic lipid turnover in the cell [10]. Therefore,
not only tumor cells but also normal cells are sensitive to ALPs
provided they are proliferating [11]. Based on these immuno-
modulatory properties and its excellent safety profile, its oral
availability and the capability to cross the blood brain barrier led
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to further investigation of edelfosine as a potential treatment in
autoimmune diseases, for instance MS.
MS is considered a prototypic CD4+ T helper cell-mediated
demyelinating autoimmune disease of the central nervous system
(CNS) [12]. Hallmarks of MS pathology are inflammatory lesions
within the CNS, de- and partial remyelination of axons, axonal
and neuronal loss and glial scarring [12]. Etiologically, MS is
considered a typical complex genetic disorder with multiple
variants of genes contributing to MS risk [13], however with small
effects at the level of the individual gene. The only exception is the
major histocomplatibility complex (MHC in general; HLA in
humans) HLA-DR15 haplotype, which has first been described as
MS risk factor in 1973 [14] and since then has remained the most
important individual risk factor, to which between 10 to 60% of
the genetic risk in MS has been attributed [15]. Variations in the
two cytokine receptor subunits IL-7RA and IL-2RA and in
numerous other genes have been described as additional risk
alleles for MS, and interestingly, many of these are involved in T
cell activation, -proliferation and -function [16,17]. While it is
currently not clear for most of the known risk genes how they
contribute to disease at the functional level, we recently
demonstrated that autologous/homeostatic T cell proliferation is
elevated in MS, and that this effect is related to the HLA-DR15
haplotype [18]. Established environmental risk factors are Epstein-
Barr virus infection [19], low vitamin D levels [20] and smoking
[21]. Besides the above genetic and environmental MS risk factors
which strongly support the autoimmune nature of the disease,
investigators have extensively examined animal models that share
similarities with MS, particularly the EAE model [22]. Animal-
and human studies point to a central role for autoreactive CD4+ T
cells in MS pathogenesis.
Consistent with the above data, currently approved MS
treatments target the autoimmune inflammation and act as
immunosuppressants/immunomodulators. High dose glucocorti-
coids are used during MS relapses as acute intervention, while the
peptidic mixture glatiramer acetate and particularly several
formulations of interferon (IFN)-b have been used now for almost
two decades as first-line therapies in relapsing-remitting MS. In
very active patients or upon failure to respond to first-line drugs,
immunosuppressants with unspecific effects, mitoxantrone, or the
anti-VLA-4 antibody natalizumab, which specifically inhibits the
migration of activated T cells into the CNS, are used to escalate
treatment intensity. All the above drugs need to be injected or
infused, but recently several oral drugs have been approved.
Fingolimod, a sphingosine 1 phosphate receptor agonist, which
traps certain T cell populations in secondary lymphoid organs, was
the first oral treatment for MS three years ago, and now two
additional compounds, teriflunomide and fumaric acid, have been
approved. The first-line treatments glatiramer acetate and IFN-b
have an overall very benign safety profile, but need to be injected.
The more effective natalizumab is also usually well tolerated, but
the development of progressive multifocal leukoencephalopathy
(PML), an opportunistic infection of the brain with the poly-
omavirus JC, constitutes a very serious side effect. Fingolimod,
although generally safe, has led to macular edema in the eye,
cardiovascular side effects, and complications with reactivation of
latent herpes virus infections including a few deaths. The safety
profile of the recently approved drugs teriflunomide and fumaric
acid remains to be determined. When considering the fact that
relatively large percentages of patients do not respond or respond
only incompletely to some of the above drugs and taking into
account their potential side effects, there is still a need for
additional, orally available and safe drugs with novel mechanism/s
of action. We therefore examined the effect of edelfosine on
human CD4+ T cells with the goal to assess whether this ‘‘old’’
compound might be useful as an immunomodulatory treatment in
MS.
Results
Edelfosine induces cell death in a concentration-
dependent manner in CD4+ and CD8+ T cells
To examine the effect of various edelfosine concentrations on
human T cells and to determine a possible damaging range of
concentrations, peripheral blood mononuclear cells (PBMCs) were
isolated from human blood and incubated for 24 h in presence of
various edelfosine concentrations. After gating on CD4+ and
CD8+ populations apoptotic cells and dead cells were analyzed by
examining annexin V+ and/or propidium iodide (PI)+ cell
populations (Fig. 1A). The incubation of PBMCs with 10 mg/ml
edelfosine led to a decrease of the annexin V2PI2 frequencies in
CD4+ T cells compared to frequencies without edelfosine, with
1 mg/ml or 3.3 mg/ml edelfosine (Fig. 1B). The incubation in the
presence of 33.3 mg/ml edelfosine resulted in only 2.0% annexin
V2PI2CD4+ T cells, i.e. only a minority of cells did not show signs
of apoptosis/cell death. Correspondingly, the frequencies of
annexin V+PI+CD4+ T cells increased reaching a maximum after
culture in the presence of 33.3 mg/ml edelfosine. Here, the
frequencies of annexin V+PI2CD4+ T cells showed only a mild
increase with increasing edelfosine concentrations. Similarly,
annexin V+PI2CD8+ and annexin V+PI+CD8+ populations
displayed a comparable increase in frequencies with increasing
edelfosine concentration. Thus, 33.3 mg/ml edelfosine appeared to
interfere massively with cell viability. Frequencies remained
unchanged upon culture without edelfosine and also with 1 mg/
ml, 3.3 mg/ml or 10 mg/ml edelfosine. By affecting cellular
viability in unstimulated T cells, at higher concentrations
edelfosine may also interfere with the cells’ functional capacity
to respond to antigen and to proliferate. This introductory
experiment confirmed previous seminal findings which state that
an apoptotic response is optimally induced in vitro after treatment
with 3–5 mg/ml edelfosine [23], e.g. Cabaner et al. applied 5 mg
edelfosine to study apoptosis induction in PBLs cultured at 16106
cells/ml cell culture medium [4], and several other groups describe
apoptosis induction in the same dose range [24,25].
Edelfosine interferes with proliferation of human PBMCs
and of antigen-specific T cell lines
As we aimed at investigating functions of edelfosine with respect
to its application as an oral drug in MS and other autoimmune
diseases, we examined the drug’s effect on homeostatic prolifer-
ation. Our recent observation that MS patients show increased
homeostatic proliferation underscores the potential involvement of
this physiological process in autoimmune conditions [18]. In order
to characterize the influence of edelfosine on the proliferation of
human T cells, PBMCs were first stimulated with a mitogenic
stimulus, PHA. We first examined the effect of edelfosine on T cell
activation and proliferation by adding edelfosine immediately
when seeding the cells (Fig. 2A). A reduction in proliferation was
already detectable upon addition of 1.0 mg/ml edelfosine and also
found at higher concentrations. Interestingly, unstimulated con-
trols, i.e. cells seeded without antigenic or mitogenic stimulus also
showed a reduction in cellular proliferation at concentrations of
1 mg/ml edelfosine or higher. The second approach aimed at
characterizing the influence on already proliferating cells (Fig. 2B).
Here, cells were activated with PHA, and edelfosine was added
two days later. Concentrations of 3.3 mg/ml edelfosine or higher
reduced proliferation. Since edelfosine affects the viability of
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unstimulated cells at higher concentrations, it may also compro-
mise the capacity of T cells to proliferate upon stimulation. To
address this issue PBMCs were incubated with or without
edelfosine for 24 h. Prior to stimulation with PHA or only adding
media, cells were washed extensively to remove edelfosine followed
by further culturing for three days (Fig. 2C). In control approaches
cells were incubated without PHA. Cells were found to retain their
proliferative function after incubation with edelfosine at concen-
trations of up to 1 mg/ml. 3.3 mg/ml edelfosine or higher
interfered with the cellular capacity to proliferate upon stimulation
with PHA. With regard to unstimulated cells, no significant
reductions of proliferation were identified following pre-incubation
with edelfosine and subsequent washout. These results are in
agreement with our introductory findings on the induction of cell
death by edelfosine (Fig. 1) and with previous data [6,23]. To
investigate further the influence of edelfosine on T cell prolifer-
ation in the context of antigen-specific stimulation, T cell lines
(TCLs) specific for MBP(83–99) were used. Edelfosine was added
Figure 1. Edelfosine impact on T cell viability. (A) Gating strategy to determine frequencies of annexin V+ and/or PI+ CD4+ as well as CD8+ T
cells. Dot plots for annexin V and PI gating of approaches in absence of edelfosine, with 10 mg/ml edelfosine, or 33.3 mg/ml edelfosine. (B) With
regard to CD4+ T cells just 10 mg/ml edelfosine led to a decrease in annexin V2PI2 frequencies accompanied by a remarkable increase in annexin
V+PI+CD4+ T cell frequencies. In the case of CD8+ T cells a marked decrease in annexin V2PI2 cells was only observed with 33.3 mg/ml edelfosine
which resulted in comparable frequencies of annexin V+PI2 as well as annexin V+PI+ cells. PBMCs of a donor were seeded in triplicates and pooled
before analysis.
doi:10.1371/journal.pone.0091970.g001
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immediately after seeding of cells (Fig. 2D). After three days of
culture 1.0 mg/ml edelfosine already profoundly reduced T cell
proliferation in stimulated as well as unstimulated conditions.
Additionally, PBMCs were incubated for up to seven days without
the addition of a stimulus (Fig. 2E). Cells were cultured in medium
alone, in presence of anti-HLA-DR- and anti-MHC class I-
blocking antibody or with 3.3 mg/ml edelfosine. Both the addition
of the antibodies and edelfosine resulted in considerably lower
proliferation. In the case of edelfosine the proliferation was
reduced to baseline levels (Fig. 2E, Supplementary Fig. S1). These
results indicate an effect of edelfosine on cellular proliferation even
if cells were not activated by adding a defined stimulus, i.e. in the
unstimulated condition or homeostatic proliferation setting.
Transcriptome analysis of CD4+ T cells identifies novel
mechanisms of action of edelfosine
We next performed genome-wide expression studies with
human CD4+ T cells to characterize, which mechanisms were
involved in the above activities of edelfosine on T cells, and
whether it exerts as yet unknown, additional effects. Unstimulated
human CD4+ T cells were exposed to two concentrations of
edelfosine (low: 3.3 and high: 10 mg/ml) and stimulated CD4+ T
cells only to the low concentration. Edelfosine modulated the gene
expression both in the stimulated and unstimulated condition,
although to a more limited extent in the latter (Table 1). Except for
the TCF4 gene, every gene that was significantly downregulated at
the low edelfosine concentration in unstimulated CD4+ T cells was
also observed at the high one. At the high dose 11 genes were up-
(signal log ratio (SLR) $0.8) and 60 downregulated (SLR #20.8).
Therefore, we focused for further analysis of unstimulated cells on
the high edelfosine dose. Subsequently, the database for annota-
tion, visualization and integrated discovery (DAVID) was used to
annotate the differentially expressed genes to functional themes/
groups and assign to them gene-ontology (GO) terms for specific
pathways of cellular function [26]. Tables 2A and -B summarize
the top-3 GO-terms, which were selected due to their P-values. As
expected from previously known mechanisms, edelfosine upregu-
lated genes associated with apoptosis and cell death in unstimu-
lated CD4+ T cells, which is consistent with the above detection of
annexin V and PI after edelfosine incubation (Table 2A). A novel
and interesting finding was the downmodulation of MHC class II-
associated genes and genes related to antigen processing and
presentation (Table 2A). In stimulated CD4+ T cells edelfosine
downregulated genes involved in cell cycle progression and
upregulated apoptosis-related genes. Again, a set of unexpected
genes that were upregulated by edelfosine has been identified.
These genes are involved in immune responses in general and
responses to virus. Interestingly, most of these genes were found to
be type I IFN-associated genes (Table 2B).
We then focused on the genes related to the newly identified
biological pathways that are modulated by edelfosine. Supple-
mentary Table S1A lists the genes related to MHC class II, and
antigen processing and immunoglobulin/B cell regulation that
were significantly downregulated in unstimulated cells upon
exposure to edelfosine. The second gene list depicts genes that
were upregulated by stimulated CD4+ T cells in the presence of
edelfosine (Supplementary Table S1B) and which have been
validated by real-time RT-PCR for IFIT1, IFIT2, IFIT3 and
IFI44 (Supplementary Fig. S2). Among the genes that are known
to be regulated by type I IFN are some that were previously
detected in a longitudinal gene expression study of PBMCs derived
from IFN-b-treated MS patients [27].
Supplementary Figures S3A and –B attempt to visualize the
effects of edelfosine by creating heatmaps. The first heatmap
focuses on the downregulated genes related to MHC class II,
antigen processing and –presentation, and immunoglobulin/B cell
regulation (Supplementary Fig. S3A). The heatmap indicates the
consecutive downregulation of genes with increasing edelfosine
concentration. Only genes with at least one SLR #20.8 in all
three possible pairwise comparisons are shown. The second
heatmap shows upregulated genes related to immune response and
anti-viral response by comparing the ‘‘unstimulated’’ condition to
the conditions ‘‘stimulated’’ and ‘‘stimulated in the presence of
3.3 mg/ml edelfosine’’ (Supplementary Fig. S3B). The heatmap
emphasizes the consistent upregulation of immune and virus
response-associated, type I IFN-related genes upon stimulation in
presence of 3.3 mg/ml edelfosine. In summary, edelfosine treat-
ment of unstimulated T cells led to the downregulation of MHC
class II genes and a type I IFN signature could be identified in
stimulated T cells. Both effects of edelfosine may alone or jointly
be responsible for the reduced proliferation.
Edelfosine-induced downmodulation of MHC class II
surface expression of B cell subsets
The microarray studies of CD4+ T cells revealed that resting,
i.e. unstimulated cells downregulated the expression of genes
associated with MHC class II antigen presentation in the presence
of edelfosine. Since CD4+ T cells are not considered ‘‘classical’’
antigen-presenting cells (APCs), we therefore examined HLA-DR/
DP/DQ expression in CD4+ and CD8+ T cells and additionally in
B cells as classical APCs. PBMCs were incubated for 24 h without
edelfosine, in presence of 3.3 mg/ml or 10 mg/ml edelfosine. After
excluding dead cells CD19+ B cells were selected (Fig. 3A). The
further subdivision by the surface markers IgD and CD27 allowed
to define the effect of edelfosine on MHC class II expression of
distinct B cell populations. Adult peripheral blood B lymphocytes
can be divided by these markers into discrete subsets with
increasing differentiation: IgD+CD272, IgD+CD27+ and
IgD2CD27+ B cells. The median fluorescence intensities (MedFIs)
for HLA-DR/DP/DQ expression on B cell subsets were
determined by flow cytometry (Fig. 3B). With regard to CD19+
B cells en bloc, but also for IgD+CD272 and IgD+CD27+ B cell
subsets the culture with edelfosine resulted in a concentration-
dependent downregulation of HLA-DR/DP/DQ expression on
the cell surface (Fig. 3C, Supplementary Table S2A). In
comparison, the expression levels appeared to be rather low on
IgD2CD27+ memory B cells. In the latter population no
differences in HLA-DR/DP/DQ expression levels were found.
Since edelfosine was initially found to affect MHC class II-related
genes in CD4+ T cells the impact of edelfosine on HLA-DR/DP/
DQ expression of T cells was also assessed. After PBMC isolation
followed by incubation for 24 h, cells were stained to gate on
CD4+ and CD8+ T cells preceded by the exclusion of dead cells
(Fig. 4A). The MedFIs for HLA-DR/DP/DQ expression on naı¨ve
and memory CD4+ and CD8+ T cells were determined (Fig. 4B).
Memory T cells, which showed an approximately 2-fold higher
HLA-DR/DP/DQ expression compared to naı¨ve T cells, pointed
to a comparable tendency in reduced HLA class II expression as
found in B cells (Fig. 4C, Supplementary Table S2B). Hence, in
the case of B cells as classical HLA-DR/DP/DQ-expressing APCs
the impact of edelfosine on MHC class II expression previously
identified by microarray analysis was verified.
Edelfosine reduces IFN-c secretion of stimulated CD4+ T
cells
Whole genome expression analysis of activated, edelfosine-
treated CD4+ T cells indicated the upregulation of genes with close
Edelfosine Modulates CD4+ T Cell Responses
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association to immune response and response to virus. To exclude
that this upregulation of type I IFN-associated genes was due to
the presence of IFN-a or -b in the cell culture medium, cell culture
supernatants were analyzed by ELISA to determine the concen-
trations of IFN-a and IFN-b, but also IFN-c. IFN-a as well as
IFN-b were virtually undetectable by ELISA in supernatants of
stimulated CD4+ T cells after 30 h of incubation in both absence
or presence of 3.3 mg/ml edelfosine. Instead, supernatants of cells
cultured without edelfosine contained 3,606.096525.12 pg/ml
IFN-c. 3.3 mg/ml edelfosine reduced IFN-c levels to
940.78681.23 pg/ml, which is equivalent to a 23.83-fold
reduction (Fig. 5A). The downmodulation of IFN-c was verified
by using the flow cytometry-based human Th1/Th2/Th9/Th17/
Th22 13plex Kit FlowCytomix (Fig. 5B). Edelfosine led to an IFN-
c-reduction from 1,462.766282.26 pg/ml to 552.93686.61 pg/
ml (22.65-fold less). Moreover, the Th1-related cytokines IL-2
and TNF-a were also reduced in comparison to their respective
controls in absence of edelfosine. Furthermore, Th17-associated
cytokines IL-17A, IL-22, as well as IL-6 were reduced by
edelfosine.
Discussion
Despite enormous progress in the development of MS
treatments there remains a need for therapies that combine high
efficacy with oral availability, that have a novel mechanism of
action and at the same time exhibit few and only minor side
effects. Increased autologous/homeostatic proliferation in the
context of HLA-DR15 in MS [18] probably influences the
composition of the immune repertoire and might contribute to MS
pathogenesis at several levels. Together with the observation that
homeostatic proliferation contributes to secondary autoimmune
diseases following treatment of MS patients with alemtuzumab
[28], it provides an interesting rationale for new treatments of MS.
Based on the data presented here, we assume that the synthetic
ether lipid edelfosine, which efficiently blocks homeostatic
proliferation, appears an interesting option. In addition to its
documented benign safety profile in humans [25,29] and oral
availability edelfosine shows interesting and novel mechanisms of
action, which are discussed below.
Regarding its effects on T cells the concentration of edelfosine
determines whether it induces apoptosis, which is well documented
by prior data [6], or preferentially prevents cell proliferation as we
demonstrate here. Due to its chemical structure edelfosine inserts
into the lipid bilayer of plasma membranes, where it integrates
into lipid rafts thereby recruiting Fas/CD95, FADD and caspase-8
[6]. These DISC-raft clusters are implicated to elicit FasL-
independent apoptosis, and the number of drug molecules per cell,
the cell density/dilution and the cell types are important
determinants of the drug’s cellular toxicity at higher concentra-
tions [30]. In our study edelfosine also interfered with the
activation and proliferation of mitogen-stimulated PBMCs in a
dose-dependent manner. Results are in agreement with the data
on apoptosis induction and cell death since the frequencies of
viable CD4+ T cells were reduced at concentrations of 10 mg/ml
edelfosine or higher, while lower concentrations did not affect cell
viability, but effectively interfered with T cell proliferation after
preincubation and also when added during or 48 h after T cell
activation.
These effects were observed with mitogen-activated cells and
also with antigen-specific T cells, i.e. myelin-specific TCLs. Our
data not only show the inhibition of proliferation of activated cells
by edelfosine, but also of cells that have not been stimulated by the
addition of peptide MBP(83–99). Hence, edelfosine interferes with
proliferation following full activation of T cells with either mitogen
or specific antigen, but also with the ‘‘background’’-proliferation in
the unstimulated control condition. The latter proliferation may
reflect at least in part a process named ‘‘homeostatic prolifera-
tion’’. Homeostatic proliferation depends on contact to self
peptide-MHC ligands and cytokines (e.g. IL-7) provided by other
cells, e.g. classical APCs and probably T cells, in order to prevent
apoptosis of T cells that have not been activated by their cognate
antigen [31,32]. Such interactions are important for thymic
selection and peripheral maintenance [33,34]. Also, both animal
experiments and data with human myelin-specific T cell clones
have shown that contact between fully activated dendritic cells and
T cells may induce distinct activation (induction of IL-12Rb2 and
IFN-c expression, Ca2+ currents) and long term survival of T cells
upon cell-cell contact [35,36]. Besides its physiological roles, our
[18] and other investigators’ recent data [28] indicate that
homeostatic proliferation is likely involved in maintaining and/
or expanding autoreactive T cells during MS with the result of
premature senescence of T cells and narrowing of the T cell
repertoire [37] and probably also a factor that contributes to
increased secondary autoimmunity following treatment with the
depleting anti-CD52 antibody alemtuzumab [28]. Based on these
considerations the inhibition of T cell proliferation at lower
Figure 2. Human T cell proliferation was affected by edelfosine. (A) Reduced PBMC proliferation upon addition of edelfosine on cell seeding
was independent of the addition of PHA. Notably, PHA-activated cells appeared to be susceptible to edelfosine at 10-fold lower concentrations. (B)
The inhibitory effect of edelfosine was observed if the drug was added to already activated, proliferating T cells, i.e. two days after cell seeding and
PHA addition. Here, a significant reduction of proliferation in unstimulated cells was only detectable with 33.3 mg/ml edelfosine. (C) Preincubation of
PBMCs with at least 3.3 mg/ml edelfosine interfered with the cells’ capacity to proliferate upon PHA stimulation. No effect was detected in
preconditioned, but unstimulated cells (experiments A, B, C: sample size n = 3 donors, each approach was seeded in triplicates and means for each
donor are represented by symbols N,&,m). (D) 1 mg/ml edelfosine or higher concentrations profoundly diminished proliferation in MBP(83–99)-specific
TCLs. One representative TCL of two is shown. Cells were incubated in quadruplicates. N stimulated,& unstimulated (E) PBMCs of one donor were
cultured without addition of a stimulus. Proliferation was detectable after seven days. The presence of anti-HLA-DR- and anti-MHC class I-blocking
antibodies or 3.3 mg/ml edelfosine inhibited cellular proliferation (N untreated, & blocking antibodies added, m 3.3 mg/ml edelfosine-treated). Bars
represent mean values 6 SEM, *P,0.05, **P,0.01 and ***P,0.001 after repeated measures ANOVA succeeded by Bonferroni post-hoc analysis.
doi:10.1371/journal.pone.0091970.g002
Table 1. Modulated gene expression in CD4+ T cells upon
culture with edelfosine.
Pairwise comparison SLR #20.8 SLR $0.8
Unstimulated
3.3 mg/ml edelfosine vs. no edelfosine 21 0
10 mg/ml edelfosine vs. no edelfosine 60 11
Stimulated
3.3 mg/ml edelfosine vs. no edelfosine 665 288
Numbers of differentially up- or downregulated genes after incubation with
edelfosine are shown.
doi:10.1371/journal.pone.0091970.t001
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concentrations of edelfosine that do not induce apoptosis is of
interest, although extrapolations from our in vitro experiments to
the in vivo situation in patients need to be done with caution.
In order to develop a better understanding, which mechanisms
contribute to the above in vitro effects of edelfosine, we performed
gene expression profiling studies with purified human CD4+ T
cells. These confirmed known mechanisms of edelfosine such as
apoptosis induction and cell cycle arrest, but also demonstrated
previously unknown activities that may explain the above effects
on T cell proliferation. At non-toxic concentrations (3.3 mg/ml)
edelfosine interferes with CD4+ T cell proliferation of activated T
cells and after preincubation, and also inhibits homeostatic T cell
proliferation. Based on these data and the induction of apoptosis/
cell death at 10 mg/ml edelfosine, gene expression profiling was
performed with 3.3 mg/ml or 10 mg/ml edelfosine. At both
concentrations a clear and unexpected downmodulation of genes
assigned to immune response and antigen processing and
presentation via MHC class II was observed (lowest GO P-value:
3.9610214 at 10 mg/ml edelfosine). This result is of interest in
several respects. MHC class II on professional and non-profes-
sional APCs (DCs, B cells, macrophages, thymic epithelial cells)
serve as recognition structures that present antigenic peptides to
the T cell receptor (TCR) of CD4+ T cells and hence are central
for physiological immune responses against pathogens, but also in
the context of autoimmune diseases like MS. In MS, down-
modulation of HLA class II or molecules involved in class II-
associated processing by edelfosine may therefore affect the
processing and presentation of autoantigens. Since interactions
of autoreactive TCRs with HLA/peptide complexes are usually of
lower avidity [38], we assume that these will be blocked more
efficiently than responses to e.g. viral peptides. Moreover, since
HLA/self-peptide complexes are besides IL-7 the strongest
stimulus for homeostatic proliferation, edelfosine will probably
act on this aspect in vivo as well as indicated by our above data. We
have previously shown that B cells upregulate HLA class II during
homeostatic proliferation experiments in vitro [18], and therefore
edelfosine may influence this mechanism in vivo based on the
reduction of HLA class II expression on B cells. Further, mouse-
and human experimental data demonstrated that class II
expression is involved in T cell-DC interactions in the absence
of nominal antigen [35,36]. In all these settings downmodulation
of MHC class II by edelfosine can impact on both antigen-driven
and homeostatic proliferation. In the present experiment CD4+ T
cells were cultured without or with edelfosine in the absence of
stimulation. IFN-c concentrations were at baseline undetectable in
both conditions (not shown), and therefore deprivation of IFN-c
upon edelfosine addition probably does not account for the
observed reduced transcription of MHC class II-associated genes
and also of class II surface expression of human B cells. At present
we do not know the underlying molecular mechanisms, by which
edelfosine interferes with transcription of molecules involved in
class II-associated processing/presentation. The multiplex cyto-
kine data indicate that edelfosine may interfere with vesicular
transport of cytokines and HLA class II to the T cell surface.
Hence, it may act as an immunomodulatory drug by integration
into the phospholipid bilayer of transport vesicles and/or
endosomal compartments for MHC class II loading. However,
this remains speculation and clearly merits further study. Of
particular note in the context of MS, type I IFN-associated IRF8
was downregulated and stood out against numerous type I IFN-
associated genes which were upregulated when T cells were
stimulated and edelfosine-treated (discussed later). IRF8 is
Table 2. Clustering of up- or downregulated genes to determine biological pathways affected by edelfosine in human CD4+ T cells
after gene expression analysis.
A Setting: unstimultated + 10 mg/ml edelfosine vs. unstimulated
Up Gene Examples P-value
Apoptosis JUN, RHOB, KRAS 1.861022
Programmed cell death JUN, RHOB, KRAS 1.961022
Learning JUN, KRAS 2.261022
Down Gene Examples P-value
Immune response CD74, CD79A, IGJ, IRF8, CCL22 3.9610214
Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II CD74, IFI30, HLA-DMA, HLA-DPA1 2.2610211
Antigen processing and presentation CD74, IFI30, HLA-DMB, HLA-DRA 1.361028
B Setting: stimulated + 3.3 mg/ml edelfosine vs. stimulated
Up Gene Examples P-value
Immune response IFIH1, IFI6, IFI44L, TNFSF10, CXCR4 2.6610210
Response to virus IRF7, ISG20, IFI44, MX1, MX2, RSAD2 7.5610210
Regulation of apoptosis CASP10, CARD16, DDIT3, HSPA1A 1.061028
Down Gene Examples P-value
Cell cycle BARD1, CKS1B, E2F1, CDCA2, CCNF 3.4610281
Cell cycle phase CKS2, DMC1, E2F1, RAD51, CCNA2 2.6610280
M phase FBXO43, MAD2L1, MKI67, CENPV 3.0610277
(A) The incubation of unstimulated cells with 10 mg/ml edelfosine resulted in the upregulation of apoptosis- and cell death-associated genes. Genes involved in immune
response and antigen processing and presentation were downregulated. (B) In the case of stimulated cells which were cultured in presence of 3.3 mg/ml edelfosine the
downmodulation of cell cycle progression-related genes was found. Additionally, edelfosine resulted in the upregulation of genes assigned to immune response- and
virus response-pathways characterized by type I IFN-regulated genes.
doi:10.1371/journal.pone.0091970.t002
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involved in microgliogenesis [39]. Microglia are considered
particularly important during chronic phases of MS, and three
MS-associated SNPs within the IRF8 gene have been described
[13,40]. Therefore, downmodulation of IRF8 may be an
additional interesting effect when considering edelfosine as MS
treatment.
When activated CD4+ T cells were exposed to edelfosine it
induced the downregulation of genes involved in cell cycle
progression. This effect of edelfosine has been examined in
previous reports. Interestingly, edelfosine inhibits cell division, but
it does not interfere with nuclear division, and therefore
multinucleated cells accumulate in G2/M phase of the cell cycle
followed by apoptosis [41]. Thus, edelfosine is able to directly
induce apoptosis by DISC complex formation, but also by indirect
effects via inhibition of cytokinesis. The relative contribution of
each depends on the cell type as well as the drug dose [42]. Besides
blocking the biosynthesis of PC [7], ALPs can also interfere with
PC breakdown into phosphatidic acid (PA) by phospholipase D
and its subsequent degradation to diacylglycerol (DAG) [43]. PA
and DAG act as lipid second messengers on the MAPK pathway,
for instance the Ras/Raf/MEK/ERK pathway of cell prolifera-
tion. In this regard, the biosynthesis and turnover of phospholipids
is not only important for the maintenance of membrane integrity,
but also serves as a stock for precursors of lipid second messengers
that mediate cellular function, survival, and proliferation.
A further finding of high interest was the prominent upregula-
tion of type I IFN-associated genes upon incubating stimulated
CD4+ T cells with edelfosine. Type I IFNs bind to heterodimeric
type I IFN receptors, which are composed of IFNAR1 and
IFNAR2 subunits, which signal through phosphorylated STAT1/
STAT2 into the nucleus, where they initiate transcription of IFN-
a/b-inducible genes. IFN-a/b activates also other pathways, for
instance the formation of STAT1 homodimers can induce the
transcription of genes that contain the IFN-c-activated sequence
(GAS). Of note, cross-talk by feedback circuits have been reported
for IFN-a/b and the type II IFN, IFN-c [44,45]. Therefore, type I
and II IFNs may influence each other in terms of signaling and
production. In our experiments, type I IFNs were not detectable in
supernatants of CD4+ T cells, which indicates that the theoretical
autocrine or paracrine type I IFN-induced gene expression is
unlikely. Moreover, data from both ELISA and multiplex cytokine
detection demonstrate that edelfosine inhibits the expression and/
or secretion of IFN-c by CD4+ T cells. This effect occurs despite
the edelfosine-induced expression of type I IFN-associated genes.
However, no downregulation of IFN-c-associated genes was found
by microarray analysis. The inhibition by edelfosine affected not
only the secretion of IFN-c but also of other cytokines and
therefore is a more general effect. We therefore conclude that the
detected upregulation of type I IFN-associated genes in stimulated,
edelfosine-treated CD4+ T cells is not due to the presence of either
IFN-a or –b in the cell culture supernatant.
Several studies have examined the effects of type I IFN during
treatment of MS patients with IFN-b. Serrano-Fernandez et al.
performed a longitudinal analysis over one year of gene expression
in PBMCs during IFN-b-1b treatment of MS patients [27]. 14
significantly upregulated genes were identified at all three time
points. These had also previously been shown to be differentially
expressed upon treatment with IFN-b-1a (IFI44L, ISG15) [46,47],
IFN-b-1b (IFIT3, SN/SIGLEC1) [48] or both (EI2AK2, IFI6,
IFI44, IFIH1, IFIT1, IFIT2, MX1, OASL, RSAD2 and XAF1)
[46–50]. Further IFN-b treatment-related biomarkers like IL-8
were identified only directly after onset of therapy. The authors
identified IFI44L, IFIT1 and RSAD2 to show the greatest fold-
change. By incubating stimulated human CD4+ T cells with
edelfosine, these candidates were also found to be highly
upregulated (SLR: 3.3 to 3.4) and surpassed only by IFI44 (3.4)
and IFIT2 (4.1). In principle, except for SN all 14 upregulated
transcripts were also identified as upregulated genes in the case of
edelfosine-incubated stimulated CD4+ T cells. Additionally,
further type I IFN-regulated genes were identified. Functionally,
transcripts can be grouped according to their role in immune
response and/or response to virus. Stu¨rzebecher et al. compared
the differential gene expression of responders, initial responders,
who produced neutralizing antibodies in the course of treatment,
and non-responders to identify unique responder expression
profiles [51]. Responders were found to upregulate nine genes
including OAS but also TRAIL, potentially linking IFN-b
treatment to elevated apoptosis. Furthermore, type I IFNs possess
anti-proliferative properties possibly by amplifying FasL/Fas-
induced apoptosis [52] and induction of p53 [53]. For instance,
apoptosis mediated by IFN-b in melanoma cell lines was
dependent on the cleavage and activation of caspase-3, -8 and -
9, cytochrome c release from mitochondria and DNA fragmen-
tation. Moreover, the expression of TRAIL was induced [54], and
the IFN-b-inducible XAF1 may act as an intermediate regulator
for TRAIL-induced apoptosis [55].
As expected, genes attributed to the regulation of apoptosis were
also upregulated in our study. Stimulated, edelfosine-treated CD4+
T cells showed a significant upregulation of TRAIL and APRIL.
The binding of TRAIL to its receptor can activate MAPK8/JNK,
caspase-8 and -3 [56]. Like caspase-8, upregulated caspase-10 acts
as an initiator caspase independently of caspase-8 to mediate
apoptosis by Fas and TNF [57]. In this way edelfosine may induce
DISC complex formation and subsequent apoptosis in T cells in
the absence of FasL as has been shown before [6].
In summary, our results confirm and extend previous findings
that edelfosine induces multiple effects that lead to apoptosis
particularly at higher drug concentrations. We further demon-
strate several novel aspects of edelfosine mechanisms of action
including the downmodulation of HLA class II molecules and
molecules involved in the class II-associated processing/presenta-
tion pathway, and further the upregulation of a large set of type I
IFN-regulated genes. Its oral availability and very good tolerability
and safety, which have already been shown in several clinical trials
[25,29], together with the above mechanisms of action add to a
drug profile that is very interesting in the context of treating
autoimmune diseases such as multiple sclerosis.
Figure 3. Edelfosine impact on HLA-DR/DP/DQ expression on human B cells. (A) Gating strategy to identify viable CD19+ B cells and their
IgD+CD272, IgD+CD27+ and IgD2 CD27+ subsets after the incubation of PBMCs for 24 h in the absence of edelfosine or in the presence of 3.3 mg/ml
and 10 mg/ml edelfosine, respectively. (B) Histograms, exemplary of one donor, display the edelfosine-induced downmodulation of HLA-DR/DP/DQ
on the previously described B cell subsets in comparison to the respective untreated control approach. (C) Summary of MedFI values determined for
each treatment within each B cell subset (n = 3 donors (represented by symbols N,&, m), + edelfosine added as indicated, 2 no edelfosine added).
For CD19+, IgD+CD272 and IgD+CD27+ populations significant reductions of HLA-DR/DP/DQ expression were observed (*P,0.05, **P,0.01,
***P,0.001 after repeated measures ANOVA and Bonferroni post-hoc analysis). Histogram legends for B: no edelfosine (black line), 3.3 mg/ml
edelfosine (green line), 10 mg/ml edelfosine (red line), isotype control (blue line).
doi:10.1371/journal.pone.0091970.g003
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Materials and Methods
Ethics Statement
The protocol, under which the studies were pursued, was
approved by the responsible local IRB, i.e. the Ethik Kommission
der A¨rztekammer Hamburg (Number of approved protocol:
2758). All participants signed a written informed consent prior
to donating any samples, and the consent documents were part of
the abovementioned, approved protocol. Consent documents are
kept on file as part of the conduct of studies with human samples
according to international standards and as stipulated by the
responsible IRB.
Preparation of edelfosine
For in vitro experiments dilutions of dissolved edelfosine
(medmark) in dest H2O were prepared and stored at 220uC
until use.
Isolation of human PBMCs
Buffy coats were diluted with PBS (PAA) and PBMCs were
separated by Ficoll (PAA) gradient centrifugation (6506g, 30 min,
Figure 4. Edelfosine impact on HLA-DR/DP/DQ expression on human T cells. (A) Gating strategy to identify viable CD4+ and CD8+ T cells
and their naı¨ve (CD27+CD45RA+) and memory (CD27+CD45RA2) subsets after the incubation of PBMCs for 24 h in the absence of edelfosine or in the
presence of 3.3 mg/ml and 10 mg/ml edelfosine, respectively. (B) Representative histograms of one donor display the considerably low expression of
HLA-DR/DP/DQ on the previously described T cell subsets. (C) Summary of MedFI values determined for each treatment within each T cell subset
(n = 3 donors (represented by symbols N,&, m), + edelfosine added as indicated, 2 no edelfosine added). For CD27+CD45RA+ and CD27+CD45RA2
populations of CD4+ and CD8+ T cells no significant reduction of HLA-DR/DP/DQ expression was observed after Bonferroni post-hoc analysis
(depicted P-value: as determined by repeated measures ANOVA). Histogram legends for B: no edelfosine (black line), 3.3 mg/ml edelfosine (green
line), 10 mg/ml edelfosine (red line), isotype control (blue line).
doi:10.1371/journal.pone.0091970.g004
Figure 5. Cytokine secretion was modulated in activated CD4+ T cells by edelfosine. (A) By ELISA, a significant reduction of IFN-c-secretion
was monitored upon edelfosine treatment. (B) This result was confirmed by a human 13plex kit which allowed the detection of not only reduced
concentrations of IFN-c in supernatants of edelfosine-treated cells, but also reduced concentrations of the Th1-associated cytokines IL-2 and TNF-a as
well as the Th17-associated cytokines IL-17A, IL-22 and IL-6. Cells of four individuals (age-matched, two males and two females) were used, error bars
indicate SEM of respective means (*P,0.05 after paired t-tests).
doi:10.1371/journal.pone.0091970.g005
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RT). Mononuclear cells which accumulated at the interphase were
resuspended in ice-cold PBS and centrifuged (5506g, 10 min,
4uC). Cells were washed in ice-cold PBS and spun down (3506g,
5 min, 4uC). The cell number was determined by staining of cells
with Tu¨rks Blue (Merck).
Generation of human antigen-specific T cell lines
T cells specific for MBP(83–99) were prepared from PBMCs of a
HLA-DR15-positive MS- patient. In brief, 26105 PBMCs per well
were seeded in 96-well plates (Greiner Bio-One) in complete TCL
medium (1% penicillin/streptomycin (Gibco), 0.05 g/l gentamy-
cin (Lonza), 2 mM L-glutamine (Gibco), 5% human serum (PAA)
in RPMI1640 medium, GlutaMAX (Gibco)) supplemented with
10 mg/ml MBP(83–99) peptide (peptides&elephants). At day 7 after
seeding 20 IU/ml IL-2 were added to the cells. Subsequently, at
day 12 after seeding proliferating cells were counted and plated at
26105 cells/well in 96-well plates in complete TCL medium
supplemented with 10 mg/ml MBP(83–99) peptide, 20 IU/ml IL-2
on 16105 autologous feeder cells irradiated at 60 Gray. Cells were
incubated for another 12 days and the addition of IL-2 was
repeated every 3–4 days.
Cell culture experiments
Annexin V+ cells after culture with edelfosine were analyzed by
seeding PBMCs in triplicate at 26105 cells/well in 96-well plates.
Cells were cultured in X-Vivo 15 (Lonza) supplemented with
edelfosine ranging from 1 mg/ml to 33.3 mg/ml in the absence of a
stimulus. After 24 h triplicates of each approach were pooled for
flow cytometry. For gene expression analysis enriched CD4+ T
cells were obtained from buffy coats of age-matched donors (two
males, two females). Cells were plated at 26105 cells/well in 96-
well plates. Cells were cultured for 30 h in X-Vivo 15 medium or
X-Vivo 15 medium supplemented with 3.3 mg/ml edelfosine,
10 mg/ml edelfosine, bead particles coated with antibodies against
CD2, CD3, and CD28 (Miltenyi Biotec), or 3.3 mg/ml edelfosine
in combination with bead particles coated with antibodies against
CD2, CD3 and CD28, respectively. Bead particles were loaded
and used according to the manufacturer’s instructions at a ratio of
1:2 of loaded particles/cell. Cell culture supernatant was stored at
220uC and used for ELISA and 13plex FlowCytomix kit
application. To analyze the MHC class II expression of CD4+ T
cells and B cells by flow cytometry PBMCs were seeded at 26106
cells in sterile 5 ml round bottom tubes (BD Falcon). Cells were
cultured in 500 ml X-Vivo supplemented with 3.3 mg/ml or
10 mg/ml edelfosine as well as particles coated with antibodies
against CD2, CD3 and CD28 as indicated for 24 h.
[methyl-3H]-thymidine incorporation assay
To determine T cell proliferation by [methyl-3H]-thymidine
incorporation, PBMCs and T cells were seeded in 96-well plates at
26105 cells/well or 26104 cells/well in the case of TCLs. PBMCs
were incubated in X-Vivo 15 medium supplemented with a
polyclonal stimulus (beads coated with antibodies against CD2,
CD3 and CD28), mitogenic PHA (Sigma Aldrich) or with a myelin
peptide, MBP(83–99), plus 5-fold autologous feeder cells (PBMCs)
irradiated at 35 Gray for 72 h. Only in the case of the homeostatic
proliferation experiment for up to seven days (Fig. 2E) PBMCs
were cultured in AIM V serum free medium (Invitrogen)
containing human albumin including (in some conditions)
blocking antibodies against HLA-DR (L243) and MHC class I
(W6/32) at 30 mg/ml each, both provided by Hans-Georg
Rammensee (Department of Immunology, Institute for Cell
Biology, University of Tu¨bingen, Tu¨bingen, Germany). Edelfosine
was added as indicated. T cell proliferation was determined by the
incorporation of [methyl-3H]-thymidine (Hartmann Analytic)
after 72 h of incubation, if not indicated otherwise. Precisely,
1 mCi [methyl-3H]-thymidine was added to each well 16 h before
harvesting the cells. For quantification of beta particle emission the
cells were harvested, washed and analyzed by using a beta counter
(Wallac).
Flow cytometry
For cell death analysis PBMCs were washed in FACS buffer. Fc-
receptors were blocked with anti-IgG (Jackson IR). Cells were
incubated for 15 min at RT in binding buffer containing anti-
CD4-APC (RPA-T4, eBioscience) and anti-CD8-PacificBlue
(DK25, Dako) antibodies for cell surface staining as well as FITC
Annexin V (BD Pharmingen). To discriminate between viable
cells, cells that were in early apoptosis and cells that were in late
apoptosis or already dead 1 mg/ml of the vital dye PI (Sigma
Aldrich) was added 5 min prior to cell acquisition by flow
cytometry. To investigate the influence of edelfosine on MHC
class II expression by human B and T cells, cells were stained for
viability by using the LIVE/DEAD Fixable Dead Cell Stain Kit
(Invitrogen). Cells were washed with PBS, blocked and stained for
cell surface antigen expression as described before. Antibodies
were anti-CD3-PE-Cy7 (UCHT1), anti-CD4-APC (RPA-T4),
both from eBioscience, anti-CD8-PacificBlue (DK25, Dako),
anti-CD5-PerCP-Cy5.5 (L17F12), anti-CD19-V450 (HIB19), an-
ti-IgD-PE (IA6-2) and anti-HLA-DR/DP/DQ-FITC (Tu39), all
from BD Biosciences, as well as anti-CD27-APC-Alexa750 (CLB-
27/1) and anti-CD45RA-PE-Cy5.5 (MEM-56), both from Invi-
trogen. Data was acquired on an LSRII flow cytometer (BD
Biosciences) and analyzed with FACSDiva (BD Biosciences) and
FlowJo (Tree Star) software.
Enrichment of human CD4+ T cells
Negative selection of CD4+ T cells was performed by using the
CD4 T Lymphocyte Enrichment Set (BD IMag) according to the
manufacturer’s instructions. The cell number was determined by
staining with Tu¨rks Blue. 26105 cells were employed to determine
CD4+ T cell purity by flow cytometry using anti-CD3 and anti-
CD4 antibodies. A purity of more than 90% was routinely
achieved.
RNA isolation, cDNA synthesis and microarray analysis
CD4+ T cells of each approach were pooled, counted and
resuspended in TRIzol reagent (Invitrogen). For RNA isolation
Pellet Paint Co-Precipitant (Merck) and chloroform (Fluka
Chemika) were added. After mixing, cells were incubated for
2 min at RT followed by centrifugation (12,0006g, 15 min, 4uC).
The upper phase of each approach was mixed with 500 ml
isopropanol (Carl Roth). After 10 min of incubation at RT the
suspensions were centrifuged (12,0006g, 10 min, 4uC). Subse-
quently, pellets were washed in 1 ml 75% ice-cold ethanol (Carl
Roth), centrifuged (12,0006g, 5 min, 4uC) and the dried pellets
were resuspended in 100 ml DEPC-treated water (Ambion). For
RNA concentration and purification the RNeasy MinElute
Cleanup Kit (Qiagen) was used as recommended by the
manufacturer. To define the RNA concentration 1 ml per purified
RNA sample was transferred on a NanoDrop spectrophotometer
ND-1000 (Thermo Scientific). To determine the quality of the
prepared RNA the RNA 6000 Nano Kit (Agilent) was used
according to the manufacturer’s instructions. RNA samples were
heated at 70uC for 2 min prior to use. Subsequently, Nano Chips
were loaded and analyzed by using the 2100 Bioanalyzer (Agilent).
Reverse transcription of RNA to synthesize cDNA was done by
using the WT Expression Kit (Ambion). cDNA fragmentation and
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labeling was performed by applying the GeneChip WT Terminal
Labeling Kit (Affymetrix). Subsequently, probes were prepared
using the GeneChip Hybridization, Wash, and Stain Kit
(Affymetrix) and analyzed by microarray technology (Affymetrix
GeneChip Human Gene 1.0 ST Array). The gene expression scan
was performed with the GeneChip Command Console 3.0
Software (Affymetrix). The robust multi-array average (RMA)
algorithm was applied for background correction, using the
Expression Console 1.1 Software (Affymetrix). The samples were
quantile normalized, followed by mean signal summarization.
Hierarchical clustering, t-test and significance analysis of micro-
arrays (SAM) were performed using the TIGR multi experiment
viewer (MeV) 4.6.1 Software (TM4 Development Group).
Microarray data is available at www.ncbi.nlm.nih.gov/geo/
(GEO accession: GSE44392).
Real-time RT-PCR
RNA was used for QuantiTect Primer Assays (Qiagen) with
QuantiFast SYBR Green RT-PCR Kit (Qiagen) according to the
manufacturer’s instructions. Each real-time RT-PCR reaction was
performed in triplicates. The relative expression of treated versus
untreated cells was normalized to GAPDH expression (compar-
ative CT method). As mentioned before, CD4
+ T cells were
derived from age-matched donors (two males, two females).
ELISA
Stored cell culture supernatants were thawed, 12 wells per
approach were selected and pooled. For ELISA analysis of IFN-a
and –b as well as IFN-c according to the manufacturer’s
instructions (PBL Laboratories and BioLegend, respectively),
100 ml of mixed supernatant were used. Cytokines were quantified
by using a microplate reader (Biotek Instruments) to determine the
absorbance at 450 nm.
Analysis of cytokine production by flow cytometry
Saved cell culture supernatants were thawed, 10 wells per
approach were selected and 20 ml per well were pooled. Cytokines
secreted by CD4+ T cells were determined by applying the Human
Th1/Th2/Th9/Th17/Th22 13plex Kit FlowCytomix
(eBioscience) according to the manufacturer’s instructions. Briefly,
25 ml of mixed supernatants were incubated for 2 h at RT with an
equal volume of Bead Mixture and 50 ml Biotin-Conjugate
Mixture. Samples were washed repeatedly with Assay Buffer
(2006g, 5 min). Afterwards, samples were resuspended in 100 ml
Assay Buffer and 50 ml Streptavidin-PE Solution and incubated for
1 h at RT. Again, samples were washed repeatedly in Assay Buffer
(2006g, 5 min). For analysis with FACSDiva and FlowCytomix
Pro 2.4 (eBioscience) software, samples were resuspended in Assay
Buffer and acquired using an LSRII flow cytometer.
Statistical analysis
For analysis of human PBMC proliferation, proliferation of
MBP(83–99)-specific TCLs as well as expression of HLA by human
B and T cells Bonferroni post-hoc tests succeeded repeated
measures ANOVA. Data generated by ELISA and 13plex
FlowCytomix kit were evaluated by paired t-tests, microarray
data was examined by t-test analysis (adjusted P-value for
significant genes: P,0.01).
Supporting Information
Figure S1 Homeostatic proliferation is inhibited by
edeldosine. PBMCs were derived from six donors (three males,
three females), seeded in triplicates to quintuplicates and cultured
without addition of a stimulus. Each symbol represents the mean
value for individual donors at time points and respective
treatments as indicated (N no treatment, & 1 mg/ml edelfosine,
m 3.3 mg/ml edelfosine). Proliferation of cells was detectable after
seven days, but was effectively inhibited by edelfosine. Bars
represent mean values 6 SEM, ***P,0.001 after repeated
measures ANOVA and Bonferroni post-hoc analysis.
(TIF)
Figure S2 Edelfosine-treated, stimulated CD4+ T cells
show increased expression of type I IFN-regulated
genes. In order to validate microarray-derived data, gene
expression was analyzed by real-time RT-PCR. RNA was isolated
from stimulated CD4+ T cells and stimulated, 3.3 mg/ml
edelfosine-treated CD4+ T cells after 30 h of culture. The relative
expression of IFIT1, IFIT2, IFIT3, and IFI44 by edelfosine-
treated CD4+ T cells related to untreated control CD4+ T cells was
normalized to GAPDH expression. CD4+ T cells were from two
male as well as two female age-matched donors. Each symbol is
representative of one donor, respectively. Bars represent mean
values 6 SEM.
(TIF)
Figure S3 Modulation of gene expression in human
CD4+ T cells mediated by stimulation and edelfosine
addition. (A) The incubation of cells in absence of a stimulus
resulted in an edelfosine concentration-dependent downregulation
of antigen processing- and presentation-associated genes. (B) The
activation of cells in presence of 3.3 mg/ml edelfosine resulted in a
consistent upregulation of immune and virus response-associated
genes. The values of differential gene expression changes
correspond to the SLR (red for upregulation, blue for downreg-
ulation, depicted as median-centered log2-signals). Genes are
clustered hierarchically in the dendrogram over the expression
matrix. The height of the branches is inversely proportional to the
degree of neighborhood between clusters (images generated with
R statistical platform 2.12, gplots package 2.8.0). Sample size n = 4
(two male and two female age-matched donors), adjusted P-value
for significant genes after t-test analysis: P,0.01.
(PDF)
Table S1 Summary of genes related to MHC class II,
antigen processing and presentation, and immunoglob-
ulin/B cell function (A) and genes related to immune
response and response to virus (B).
(DOCX)
Table S2 Summary of means and corresponding SEM
values for B cells (A) and T cells (B). Cell types were
analyzed to determine the effect of edelfosine treatment on HLA-
DR/DP/DQ expression.
(DOCX)
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